Evidence map›Paper›PMID 34212192›Full record

ArticleHealth policy and planning2021

Role of data from cost and other economic analyses in healthcare decision-making for HIV, TB and sexual/reproductive health programmes in South Africa.

Joshua P Murphy, Sharon Kgowedi, Nalini Naidoo, Sarah Girdwood, Lise Jamieson, Djøra Soeteman, Stephen Resch, Gesine Meyer-Rath

Open access · hybridAbstract read
In one paragraph

Article in Health policy and planning, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Joshua P MurphyHealth Economics and Epidemiology Research Office (HE2RO), University of the Witwatersrand, 39 Empire Rd, Johannesburg 2193, South Africa.ORCID 0000-0001-5466-3131
Sharon KgowediHealth Economics and Epidemiology Research Office (HE2RO), University of the Witwatersrand, 39 Empire Rd, Johannesburg 2193, South Africa.
Nalini NaidooHealth Economics and Epidemiology Research Office (HE2RO), University of the Witwatersrand, 39 Empire Rd, Johannesburg 2193, South Africa.
Sarah GirdwoodHealth Economics and Epidemiology Research Office (HE2RO), University of the Witwatersrand, 39 Empire Rd, Johannesburg 2193, South Africa.
Lise JamiesonHealth Economics and Epidemiology Research Office (HE2RO), University of the Witwatersrand, 39 Empire Rd, Johannesburg 2193, South Africa.
Djøra SoetemanCenter for Health Decision Science, Harvard T.H. Chan School of Public Health, 718 Huntington Ave, Boston, MA 02115, USA.
Stephen ReschCenter for Health Decision Science, Harvard T.H. Chan School of Public Health, 718 Huntington Ave, Boston, MA 02115, USA.
Gesine Meyer-RathHealth Economics and Epidemiology Research Office (HE2RO), University of the Witwatersrand, 39 Empire Rd, Johannesburg 2193, South Africa.
University of the Witwatersrand · ZABoston University · US

Funding

Partnership for Global Health Research Training Program (Renewal)-Supplement for OBSSR, NCI, NCI-AIDS and NIDCDD43TW010543 · FIC · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Wafaie W Fawzi, DAVIDSON HOWES HAMER · 2017 to 2026
$12.1M
Bill and Melinda Gates Foundation Improving Data, Systems, and Methods for EstimaFIC NIH HHS D43 TW010543
6 · The paper itself

Abstract

An increasing focus on the use of the results of cost analyses and other economic evaluations in health programme decision-making by governments, donors and technical support partners working in low- and middle-income countries is accompanied by recognition that this use is impeded by several factors, including the lack of skills, data and coordination between spheres of the government. We describe our experience generating economic evaluation data for human immunodeficiency virus, tuberculosis and sexual/reproductive health programmes in South Africa alongside the results of a series of in-depth interviews (IDIs) among decision-makers within the South African government and implementing organizations (data users) and producers of economic evaluations (data producers). We summarize results across (1) the process of implementing a new intervention; (2) barriers to the use of cost data and suggested solutions and (3) the transferability of experiences to the planned South African implementation of universal health coverage (UHC). Based on our experience and the IDIs, we suggest concrete steps towards the improvement of economic data use in the planning and the establishment of structures mandated under the transition to UHC. Our key recommendations include the following: (1) compile a publicly available and regularly updated in-country cost repository; (2) increase the availability of programmatic outcomes data at the aggregate level; (3) agree upon and implement a set of primary decision criteria for the adoption and funding of interventions; (4) combine the efforts of health economics institutions into a stringent system for health technology assessments and (5) improve the link between national and provincial planning and budgeting.

Indexed as

HIV InfectionsReproductive HealthCost-Benefit AnalysisDelivery of Health CareHumansSouth Africabudgetingcost datadecision-makingHealth economicsinterviewsSouth Africa

Identifiers

PMID34212192
PMCPMC8597963
OpenAlexW3176645225

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.